Could Semaglutide Help Migraine? What a 189,000-Person Study Really Shows
GLP-1 medications have transformed the treatment of obesity and metabolic disease. Now patients and clinicians are asking another intriguing question:
Could these medications also reduce migraine burden?
A nationwide Danish study published on August 5, 2026, offers an encouraging signal. Among 189,392 adults who started semaglutide for weight management, triptan consumption gradually declined after treatment began.
But this was not a migraine treatment trial—and the distinction matters.
What did the researchers study?
Investigators used Danish national prescription data to identify adults who started weight-management semaglutide between December 2022 and December 2024. The cohort was 68% female, with a median age of 50.
The researchers examined monthly triptan dispensing for 24 months before and 12 months after semaglutide initiation. Before treatment, triptan use had been gradually increasing. After semaglutide began, that upward trajectory reversed.
At 12 months:
Overall triptan consumption was approximately 7% below the level projected from the pre-treatment trend.
Among people already using triptans, consumption was approximately 14% lower than projected.
Women had an 8% relative reduction, while the change in men was not statistically significant.
The strongest associations appeared in adults ages 18–35 and in people already using migraine-preventive medication.
First-time triptan initiation did not clearly decrease.
Importantly, these percentages do not mean that patients experienced 7% or 14% fewer migraine attacks. They describe changes in dispensed medication relative to a statistical projection.
Why is the signal interesting?
The findings are consistent with a small but developing body of research suggesting that GLP-1 receptor signaling may intersect with migraine biology.
Possible mechanisms include:
Reduced systemic and neuroinflammation
Improved insulin sensitivity and metabolic stability
Weight loss and its downstream effects on migraine risk
Modulation of central pain pathways
Effects on CGRP-related signaling
Changes in cerebrospinal-fluid production or intracranial-pressure regulation
A 2025 prospective pilot study adds to the interest. Thirty-one patients with obesity and difficult-to-treat high-frequency or chronic migraine received liraglutide for 12 weeks. Mean monthly headache days decreased from 19.8 to 10.7, while BMI changed very little. However, the study was small, open-label, lacked a placebo group and evaluated liraglutide—not semaglutide.
Together, these studies create a legitimate research hypothesis. They do not establish a new migraine treatment.
What can’t this study tell us?
Triptan dispensing is a useful population-level signal, but it is not equivalent to migraine control.
The Danish study did not measure:
Monthly migraine or headache days
Attack severity or duration
Migraine-related disability
Migraine with versus without aura
Weight or BMI change
The relationship between weight loss and headache improvement
Hydration, nutrition, sleep or physical activity
Menstrual, fertility-treatment or menopausal hormone changes
Use of gepants, NSAIDs or other acute treatments
Individual changes in established migraine-preventive therapy
Only 4.5% of the entire semaglutide cohort had received a triptan during the preceding year. Therefore, the impressive overall sample size should not be confused with a clinical trial of 189,000 people with confirmed migraine.
The interrupted-time-series design is stronger than a simple before-and-after comparison, and the investigators performed several sensitivity analyses. Nevertheless, it remains observational. Lifestyle changes, increased medical attention, weight loss, medication substitutions and other unmeasured factors could have influenced the results.
The study was funded by Novo Nordisk. Two authors were company employees, and the sponsor participated in the study’s design, analysis, interpretation and manuscript preparation. The academic investigators retained access to the data and responsibility for the scientific content, but the relationship should be disclosed when interpreting the findings.
Could semaglutide also worsen headaches?
Yes, in some individuals.
Headache remains a recognized adverse reaction to semaglutide. In adult Wegovy weight-reduction trials, headache was reported in 14% of semaglutide-treated participants and 10% of those receiving placebo.
In clinical practice, nausea, vomiting, dehydration, prolonged meal gaps, excessive appetite suppression, sleep disruption and rapid medication escalation can also aggravate headaches in susceptible patients.
Population-level reassurance does not replace individual monitoring.
What should clinicians do now?
Semaglutide should not currently be prescribed solely to prevent or treat migraine. It has not been proven or approved for that purpose.
However, when a GLP-1 medication is otherwise appropriate for obesity or another approved indication, migraine should become part of the monitoring plan rather than an afterthought.
For patients with migraine, I recommend documenting:
Baseline and monthly migraine days
Total headache days
Days of triptan, gepant, NSAID or combination-rescue use
Headache-related disability
GLP-1 dose and titration dates
Hydration, nausea, vomiting and prolonged meal gaps
Weight and body-composition change
Sleep and hormonal changes
Adjustments to migraine-preventive treatment
This allows us to determine whether migraine is truly improving, remaining stable or worsening—and whether the change appears related to the medication, weight loss, metabolic improvement or something else entirely.
At Cardiel Precision Brain Health, this is why GLP-1 monitoring extends beyond the number on the scale. For a person living with migraine, changes in hydration, nutrition, muscle mass, sleep, hormones and acute-medication use can be just as clinically meaningful as weight loss.
The bottom line
The appropriate conclusion is not that semaglutide treats migraine.
The appropriate conclusion is that a biologically plausible and clinically meaningful signal has now appeared in a very large national dataset—strong enough to justify randomized trials that measure migraine days, disability, acute-medication use, metabolic response and weight change directly.
Until then, this research should change what we measure, not what we promise.
Bibliography
Roland N, Sonne H, Pellesi L, et al. Impact of semaglutide introduction on the use of triptans: an interrupted-time series. The Journal of Headache and Pain. 2026;27:199. doi:10.1186/s10194-026-02462-4.
Braca S, Russo CV, Stornaiuolo A, et al. Effectiveness and tolerability of liraglutide as add-on treatment in patients with obesity and high-frequency or chronic migraine: A prospective pilot study. Headache. 2025;65:1831–1838. doi:10.1111/head.14991.
Halloum W, Al Dughem Y, Beier D, Pellesi L. Glucagon-like peptide-1 receptor agonists for headache and pain disorders: a systematic review. The Journal of Headache and Pain. 2024;25:112. doi:10.1186/s10194-024-01821-3.
U.S. Food and Drug Administration. Wegovy prescribing information. Revised February 2026.
This article is for educational purposes and does not constitute individualized medical advice.
About the Author:
Myrna Cardiel, MD, is a board-certified neurologist and the founder of Cardiel Precision Brain Health in Manhattan. With more than two decades of clinical experience and advanced expertise in headache medicine, lifestyle medicine, obesity medicine, and menopause-related brain health, she helps adults understand how metabolism, hormones, sleep, and other whole-body factors may influence migraine and cognitive function. Her practice provides personalized, unrushed care for patients seeking a more comprehensive approach to migraine, brain fog, attention concerns, and long-term brain health.
